Kastritis E, Kyrtsonis M-C, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, Vassou A, Repousis P, Delimpasi S, Sioni A, et al. Competing risk survival analysis in patients with symptomatic waldenström macroglobulinemia: The impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica [Internet]. 2015;100(11):e448 - e449.